Stanley-Laman Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-14,000
| Closed | -$355K | – | 302 |
|
|
2025
Q1 | $355K | Sell |
14,000
-5,922
| -30% | -$155K | 0.05% | 224 |
|
|
2024
Q4 | $529K | Sell |
19,922
-30,831
| -61% | -$836K | 0.07% | 202 |
|
|
2024
Q3 | $1.47M | Sell |
50,753
-1,677
| -3% | -$48.9K | 0.21% | 137 |
|
|
2024
Q2 | $1.47M | Buy |
52,430
+2,000
| +4% | +$55.1K | 0.21% | 132 |
|
|
2024
Q1 | $1.4M | Sell |
50,430
-5,169
| -9% | -$143K | 0.2% | 137 |
|
|
2023
Q4 | $1.6M | Buy |
55,599
+44,722
| +411% | +$1.35M | 0.24% | 129 |
|
|
2023
Q3 | $361K | Hold |
10,877
| – | – | 0.06% | 188 |
|
|
2023
Q2 | $399K | Buy |
+10,877
| New | +$423K | 0.07% | 184 |
|
|
2021
Q1 | – | Sell |
-86,814
| Closed | -$3.2M | – | 258 |
|
|
2020
Q4 | $3.2M | Sell |
86,814
-381
| -0.4% | -$14K | 0.57% | 42 |
|
|
2020
Q3 | $3.04M | Buy |
87,195
+3,095
| +4% | +$109K | 0.67% | 38 |
|
|
2020
Q2 | $2.61M | Buy |
84,100
+3,697
| +5% | +$126K | 0.63% | 41 |
|
|
2020
Q1 | $2.49M | Buy |
80,403
+983
| +1% | +$33.5K | 0.76% | 39 |
|
|
2019
Q4 | $2.95M | Sell |
79,420
-3,930
| -5% | -$140K | 0.7% | 37 |
|
|
2019
Q3 | $2.84M | Sell |
83,350
-2,918
| -3% | -$106K | 0.7% | 38 |
|
|
2019
Q2 | $3.55M | Sell |
86,268
-138
| -0.2% | -$5.48K | 0.85% | 35 |
|
|
2019
Q1 | $3.48M | Sell |
86,406
-203
| -0.2% | -$8.13K | 0.85% | 36 |
|
|
2018
Q4 | $3.59M | Sell |
86,609
-8,114
| -9% | -$337K | 1% | 36 |
|
|
2018
Q3 | $3.96M | Sell |
94,723
-1,192
| -1% | -$45.9K | 0.97% | 30 |
|
|
2018
Q2 | $3.3M | Sell |
95,915
-5,280
| -5% | -$180K | 0.74% | 38 |
|
|
2018
Q1 | $3.41M | Sell |
101,195
-3,156
| -3% | -$108K | 0.78% | 37 |
|
|
2017
Q4 | $3.59M | Sell |
104,351
-181
| -0.2% | -$6.17K | 0.77% | 37 |
|
|
2017
Q3 | $3.54M | Sell |
104,532
-15,923
| -13% | -$512K | 0.95% | 35 |
|
|
2017
Q2 | $3.84M | Buy |
120,455
+95,028
| +374% | +$3M | 1.04% | 31 |
|
|
2017
Q1 | $825K | Sell |
25,427
-26,848
| -51% | -$846K | 0.22% | 111 |
|
|
2016
Q4 | $1.61M | Buy |
52,275
+2,208
| +4% | +$67.4K | 0.5% | 66 |
|
|
2016
Q3 | $1.61M | Sell |
50,067
-11,013
| -18% | -$368K | 0.66% | 27 |
|
|
2016
Q2 | $2.04M | Sell |
61,080
-17,155
| -22% | -$548K | 0.8% | 26 |
|
|
2016
Q1 | $2.2M | Sell |
78,235
-8,094
| -9% | -$231K | 0.41% | 52 |
|
|
2015
Q4 | $2.64M | Sell |
86,329
-4,404
| -5% | -$139K | 0.45% | 75 |
|
|
2015
Q3 | $2.7M | Buy |
90,733
+7,133
| +9% | +$229K | 0.55% | 55 |
|
|
2015
Q2 | $2.66M | Buy |
83,600
+1,693
| +2% | +$55.2K | 0.49% | 65 |
|
|
2015
Q1 | $2.7M | Sell |
81,907
-551
| -0.7% | -$17.5K | 0.49% | 63 |
|
|
2014
Q4 | $2.44M | Buy |
82,458
+12,785
| +18% | +$367K | 0.46% | 68 |
|
|
2014
Q3 | $1.96M | Buy |
69,673
+2,267
| +3% | +$63.6K | 0.38% | 87 |
|
|
2014
Q2 | $1.9M | Buy |
67,406
+4,900
| +8% | +$140K | 0.35% | 91 |
|
|
2014
Q1 | $1.91M | Buy |
+62,506
| New | +$1.86M | 0.33% | 98 |
|
Other funds holding PFE
Stanley-Laman Group's PFE Position: Q2 2025 in Review
Stanley-Laman Group sold out of Pfizer (PFE) in Q2 2025, closing a stake of 14,000 shares — an estimated $355K sold.
Stanley-Laman Group first reported a position in PFE in Q1 2014 and held it in 36 quarters. The position peaked at $3.96M in Q3 2018. 2,809 funds tracked by Wall St. Rank hold PFE as of Q2 2025.
- Stanley-Laman Group reported no remaining Pfizer position as of Q2 2025 after selling out during the quarter.
- Stanley-Laman Group sold 14,000 Pfizer shares in Q2 2025, an estimated $355K.
- Stanley-Laman Group first reported a position in Pfizer in Q1 2014 and held it in 36 quarters.
- Stanley-Laman Group's Pfizer position peaked at $3.96M in Q3 2018.
- 2,809 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.
Based on Stanley-Laman Group's 13F filing for Q2 2025, filed 29 Jul 2025.